{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.80","value":"127.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 1.3 mg per m\\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.","id":"OG000","title":"Bortezomib"}],"paramType":"MEAN","populationDescription":"The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.","reportingStatus":"POSTED","timeFrame":"0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1","title":"Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 11 of Cycle 1","type":"PRIMARY","unitOfMeasure":"ng per ml"}